A live webcast of the call will be available on the Company's website at www.solidbio.com under the “News & Events” tab in the Investor Relations section, or by clicking here. Participants may also access the call, by dialing 866-763-0341 for domestic callers or 703-871-3818 for international callers, referencing conference ID# 4772539.
The archived webcast will be available in the “News and Events” section of the Company's website.
About
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit www.solidbio.com.
Investor Contact:
212-867-1768
David.Carey@finnpartners.com
Media Contact:
917-497-2867
Erich.Sandoval@finnpartners.com
Source:
2021 GlobeNewswire, Inc., source